Use of firocoxib for the treatment of equine osteoarthritis

References

• Ross MW, Dyson SJ. Diagnosis and Management of Lameness in the Horse. Philadelphia, PA, WB Saunders, 2003, 1140p.
   Google Scholar
• United States Department of Agriculture. National Economic Cost of Equine Lameness, Colic and Equine Protozoal Myeloencephalitis in the United States. Washington: USDA; 2001 Available from: http://www.aphis.usda.gov/animal_health/nahms/equine/downloads/equine98/Equine98_is_EconCost.pdf. Accessed September 3, 2014.
   Google Scholar
• McIlwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease. Equine Vet J. 2010;20:3–11.
   Google Scholar
• [No authors listed] Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis. 1996;55:552–557.8774185
   PubMed Web of Science ®Google Scholar
• Lynch TM, Caron JP, Arnoczky SP, Lloyd JW, Stick JA, Render JA. Influence of exogenous hyaluronan on synthesis of hyaluronan and collagenase by equine synoviocytes. Am J Vet Res. 1998;59:888–892.9659557
   PubMed Web of Science ®Google Scholar
• Kawcak CE, Frisbie DD, McIlwraith CW, Werpy NM, Park RD. Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2007;68:598–604.17542691
   PubMed Web of Science ®Google Scholar
• Gotoh S, Onaya J, Abe M, et al Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52:817–822.8250613
   PubMed Web of Science ®Google Scholar
• Frisbie DD, McIlwraith CW, Kawcak CE, Werpy NM, Pearce GL. Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2009;70:210–215.19231953
   PubMed Web of Science ®Google Scholar
• Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res. 2007;68:290–296.17331019
   PubMed Web of Science ®Google Scholar
• Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J. 1997;29:349–359.9306060
   PubMed Web of Science ®Google Scholar
• Clegg TE, Caborn D, Mauffrey C. Viscosupplementation with hyaluronic acid in the treatment for cartilage lesions: a review of current evidence and future directions. Eur J Orthop Surg Traumatol. 2013;23:119–124.23412441
   PubMedGoogle Scholar
• Dechant JE, Baxter GM, Frisbie DD, Trotter GW, McIlwraith CW. Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Equine Vet J. 2003;35:444–450.12875321
   PubMed Web of Science ®Google Scholar
• Kawcak CE, Norrdin RW, Frisbie DD, Trotter GW, Mcilwraith CW. Effects of osteochondral fragmentation and intra-articular triamcinolone acetonide treatment on subchondral bone in the equine carpus. Equine Vet J. 1998;30:66–71.9458401
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Gotoh M, Nakama K, Yamada T, Higuchi F, Nagata K. Hyaluronic acid inhibits mRNA expression of proinflammatory cytokines and cyclooxygenase-2/prostaglandin E(2) production via CD44 in interleukin-1-stimulated subacromial synovial fibroblasts from patients with rotator cuff disease. J Orthop Res. 2008;26:1032–1037.18302264
   PubMed Web of Science ®Google Scholar
• Doucet MY, Bertone AL, Hendrickson D, et al Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. J Am Vet Med Assoc. 2008;232:91–97.18167116
   PubMed Web of Science ®Google Scholar
• Frisbie DD. Equine surgery In: Auer JA, Stick JA, editors. Musculoskeletal System: Medical Treatment of Joint Disease. 4th ed. St Louis (MO): Elsevier Saunders; 2012: 1114–1122.
   Google Scholar
• Kvaternick V, Malinski T, Wortmann J, Fischer J. Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854:313–319.
   PubMed Web of Science ®Google Scholar
• Cox S, Dudenbostel L, Sommardahl C, Yarbrough J, Saleh M, Doherty T. Pharmacokinetics of firocoxib and its interaction with enrofloxacin in horses. J Vet Pharmacol Ther. 2012;35:615–617.22233122
   PubMed Web of Science ®Google Scholar
• McIlwraith CW. From arthroscopy to gene therapy–30 years of looking in joints. Am Assoc Equine Pract. 2005;51:65–113.
   Google Scholar
• McIlwraith CW. Current concepts in equine degenerative joint disease. J Am Vet Med Assoc. 1982;180:239–250.7035425
   PubMed Web of Science ®Google Scholar
• McIlwraith CW, Van Sickle DC. Experimentally induced arthritis of the equine carpus: histologic and histochemical changes in the articular cartilage. Am J Vet Res. 1981;42:209–217.7258770
   PubMed Web of Science ®Google Scholar
• McIlwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease. Equine Vet J Suppl. 1988: 3–11.9079056
   PubMedGoogle Scholar
• Greenwald RA, Moy WW. Inhibition of collagen gelation by action of the superoxide radical. Arthritis Rheum. 1979;22:251–259.217393
   PubMed Web of Science ®Google Scholar
• Dimock AN, Siciliano PD, McIlwraith CW. Evidence supporting an increased presence of reactive oxygen species in the diseased equine joint. Equine Vet J. 2000;32:439–443.11037267
   PubMed Web of Science ®Google Scholar
• May SA, Lees P. Nonsteroidal anti-inflammatory drugs In: McIlwraith CW, Trotter GW, editors. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996: 223–237.
   Google Scholar
• Frisbie DD, Al-Sobayil F, Billinghurst RC, Kawcak CE, McIlwraith CW. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis Cartilage. 2008;16:1196–1204.18442931
   PubMed Web of Science ®Google Scholar
• Frisbie DD, Kawcak CE, Baxter GM, et al Effects of 6α-methylprednisolone acetate on an equine osteochondral fragment exercise model. Am J Vet Res. 1998;59:1619–1628.9858417
   PubMed Web of Science ®Google Scholar
• Kawcak CE, Frisbie DD, Trotter GW, et al Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation. Am J Vet Res. 1997;58:1132–1140.9328667
   PubMed Web of Science ®Google Scholar
• Teitz CC, Chrisman OD. The effect of salicylate and chloroquine on prostaglandin-induced articular damage in the rabbit knee. Clin Orthop Relat Res. 1975: 264–274.49235
   PubMedGoogle Scholar
• Tung JT, Arnold CE, Alexander LH, et al Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1β-stimulated matrix metalloproteinases 1, 3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures. Am J Vet Res. 2002;63:987–993.12118680
   PubMed Web of Science ®Google Scholar
• Goldring MB, Suen LF, Yamin R, Lai WF. Regulation of collagen gene expression by prostaglandins and interleukin-1β in cultured chondrocytes and fibroblasts. Am J Ther. 1996;3:9–16.11856992
   PubMedGoogle Scholar
• DiBattista JA, Martel-Pelletier J, Fujimoto N, Obata K, Zafarullah M, Pelletier JP. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway. Lab Invest. 1994;71:270–278.8078306
   PubMed Web of Science ®Google Scholar
• Pettersson H, Ryden G. Avulsion fractures of the caudoproximal extremity of the first phalanx. Equine Vet J. 1982;14:333–335.7173145
   PubMed Web of Science ®Google Scholar
• Nilsson G, Olsson SE. Radiologic and patho-anatomic changes in the distal joints and the phalanges of the standardbred horse. Acta Vet Scand Suppl. 1973;44:1–57.4529375
   PubMedGoogle Scholar
• Nilsson G. Lameness and pathologic changes in the distal joints and the phalanges of the standardbred horse. A correlative study. Acta Vet Scand Suppl. 1973;44:83–96.4529326
   PubMedGoogle Scholar
• Barclay WP, Foerner JJ, Phillips TN. Lameness attributable to osteochondral fragmentation of the plantar aspect of the proximal phalanx in horses: 19 cases (1981–1985). J Am Vet Med Assoc. 1987;191:855–857.3679979
   PubMed Web of Science ®Google Scholar
• McIlwraith CW, Trotter GW. Clinical feature and diagnosis of equine joint disease In: McIlwraith CW, Trotter GW, editors. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996;120–145.
   Google Scholar
• van Weeren PR, de Grauw JC. Pain in osteoarthritis. Vet Clin North Am Equine Pract. 2010;26:619–642.21056303
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235.5284360
   PubMedGoogle Scholar
• Dingle JT. Prostaglandins in human cartilage metabolism. J Lipid Mediat. 1993;6:303–312.8357988
   PubMedGoogle Scholar
• Barton MH, Paske E, Norton N, King D, Giguère S, Budsberg S. Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses. Equine Vet J. 2014;46:72–75.23662599
   PubMed Web of Science ®Google Scholar
• Duz M, Parkin TD, Marshall JF. Effect of phenylbutazone, flunixin meglumine and firocoxib on ex vivo cyclo-oxygenase activity in horses undergoing elective surgery. Equine Vet J. 2013;45:15.22506773
   PubMedGoogle Scholar
• McCann M, Anderson D, Brideau C, Black WC, Zhang GH, Hickey GJ. In vitro activity and in vivo efficacy of a novel COX-2 inhibitor in the horse. J Vet Intern Med. 2002;16:355.
   Google Scholar
• Cox S, Villarino N, Sommardahl C, et al Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen. Vet J. 2013;198:382–385.24076125
   PubMed Web of Science ®Google Scholar
• Hovanessian N, Davis JL, McKenzie HC 3rd, Hodgson JL, Hodgson DR, Crisman MV. Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals. J Vet Pharmacol Ther. 2014;37:243–251.24749691
   PubMed Web of Science ®Google Scholar
• Knych HK, Stanley SD, Arthur RM, Mitchell MM. Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses. Equine Vet J. Epub November 13, 2013.
   Google Scholar
• Racing Medication and Testing Consortium. Controlled therapeutic medications. 2013 Available from: http://www.rmtcnet.com/resources/RMTC%20Therapeutic%20Substances%20List-July%202013.pdf Accessed September 3, 2014.
   Google Scholar
• Kvaternick V, Pollmeier M, Fischer J, Hanson PD. Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. J Vet Pharmacol Ther. 2007;30:208–217.17472652
   PubMed Web of Science ®Google Scholar
• United States Equestrian Federation. 2014 Guidelines for Drugs and Medications. Columbus (OH): USEF; 2014 Available from: https://www.usef.org/documents/drugsMeds/drugsMedsGuidelines2014.pdf. Accessed September 3, 2014.
   Google Scholar
• Letendre LT, Tessman RK, McClure SR, Kvaternick VJ, Fischer JB, Hanson PD. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. Am J Vet Res. 2008;69:1399–1405.18980421
   PubMed Web of Science ®Google Scholar
• Lees P. Analgesic, antiinflammatory, antipyretic drugs In: Riviere JE, Papich MG. Veterinary Pharmacology and Therapeutics. 9th ed. Ames (IA): Wiley-Blackwell; 2009: 457–492.
   Google Scholar
• US Food and Drug Administration. Freedom of Information Summary: Equioxx Oral Paste–0.82% Firocoxib (w/w). Rockville (MD): FDA; 2005.
   Google Scholar
• Orsini JA, Ryan WG, Carithers DS, Boston RC. Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses. Am J Vet Res. 2012;73:664–671.22533398
   PubMed Web of Science ®Google Scholar
• Koene M, Goupil X, Kampmann C, Hanson PD, Denton D, Pollmeier MG. Field trial validation of the efficacy and acceptability of firocoxib, a highly selective COX-2 inhibitor, in a group of 96 lame horses. J Equine Vet Sci. 2010;30:237–243.
   Web of Science ®Google Scholar
• Kivett L, Taintor J, Wright J. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses. J Vet Pharmacol Ther. 2014;37:413–416.24354928
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Freedom of Information Summary: Equioxx Injection–firocoxib. Rockville (MD): FDA; 2010.
   Google Scholar
• Wallace JL, Reuter BK, McKnight W, Bak A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? J Clin Gastroenterol. 1998;27 Suppl 1:S28–S34.9872495
   PubMedGoogle Scholar
• Nieto JE, Aleman M, Anderson JD, Fiack C, Snyder JR. Effects of phenylbutazone on gene expression of cyclooxygenase-1 and -2 in the oral, glandular gastric, and bladder mucosae of healthy horses. Am J Vet Res. 2012;73:98–104.22204294
   PubMed Web of Science ®Google Scholar
• Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am J Vet Res. 2009;70:992–1000.19645580
   PubMed Web of Science ®Google Scholar
• MacKay RJ, French TW, Nguyen HT, et al Effects of large doses of phenylbutazone administration to horses. Am J Vet Res. 1983;44:774–780.6869982
   PubMed Web of Science ®Google Scholar
• MacAllister CG. Effects of toxic doses of phenylbutazone in ponies. Am J Vet Res. 1983;44:2277–2279.6660616
   PubMed Web of Science ®Google Scholar
• Back W, MacAllister CG, van Heel MC, Pollmeier M, Hanson PD. The use of force plate measurements to titrate the dosage of a new COX-2 inhibitor in lame horses. Equine Vet J. 2009;41:309–312.19469242
   PubMed Web of Science ®Google Scholar
• Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study. J Am Vet Med Assoc. 1984;184:699–703.6725103
   PubMed Web of Science ®Google Scholar
• Keegan KG, Messer NT, Reed SK, Wilson DA, Kramer J. Effectiveness of administration of phenylbutazone alone or concurrent administration of phenylbutazone and flunixin meglumine to alleviate lameness in horses. Am J Vet Res. 2008;69:167–173.18241011
   PubMed Web of Science ®Google Scholar
• Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. J Vet Pharmacol Ther. 1995;18:187–195.7674454
   PubMed Web of Science ®Google Scholar
• Owens JG, Kamerling SG, Stanton SR, Keowen ML, Prescott-Mathews JS. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Am J Vet Res. 1996;57: 866–874.8725815
   PubMed Web of Science ®Google Scholar
• Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005;52:302–306.15939622
   PubMed Web of Science ®Google Scholar
• Lees P, McKellar Q, May SA, Ludwig B. Pharmacodynamics and pharmacokinetics of carprofen in the horse. Equine Vet J. 1994;26: 203–208.8542839
   PubMed Web of Science ®Google Scholar
• Raidal SL, Edwards S, Pippia J, Boston R, Noble GK. Pharmacokinetics and safety of oral administration of meloxicam to foals. J Vet Intern Med. 2013;27:300–307.23425143
   PubMed Web of Science ®Google Scholar
• Vander Werf KA, Davis EG, Kukanich B. Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. J Vet Pharmacol Ther. 2013;36:376–381.23067209
   PubMed Web of Science ®Google Scholar
• Sanderson RO, Beata C, Flipo RM, et al Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164:418–424.19346540
   PubMed Web of Science ®Google Scholar
• Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27:1011–1019.23782347
   PubMed Web of Science ®Google Scholar
• de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J. 2009;41:693–699.19927589
   PubMed Web of Science ®Google Scholar
• McKellar QA, Bogan JA, von Fellenberg RL, Ludwig B, Cawley GD. Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. Equine Vet J. 1991;23:280–284.1915228
   PubMed Web of Science ®Google Scholar
• Liesegang A, Limacher S, Sobek A. The effect of carprofen on selected markers of bone metabolism in dogs with chronic osteoarthritis. Schweiz Arch Tierheilkd. 2007;149:353–362.17803115
   PubMed Web of Science ®Google Scholar
• Williams A, Smith JR, Allaway D, Harris P, Liddell S, Mobasheri A. Carprofen inhibits the release of matrix metalloproteinases 1, 3, and 13 in the secretome of an explant model of articular cartilage stimulated with interleukin 1β. Arthritis Res Ther. 2013;15:R223.24373218
   PubMed Web of Science ®Google Scholar